Blank SV - Search Results

1

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR. Aghajanian C, et al. Among authors: blank sv. J Clin Oncol. 2012 Jun 10;30(17):2039-45. doi: 10.1200/JCO.2012.42.0505. Epub 2012 Apr 23. J Clin Oncol. 2012. PMID: 22529265 Free PMC article. Clinical Trial.

2

Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium.

Yi-Shin Kuo D, Timmins P, Blank SV, Fields AL, Goldberg GL, Murgo A, Christos P, Wadler S, Runowicz CD. Yi-Shin Kuo D, et al. Among authors: blank sv. Gynecol Oncol. 2006 Jan;100(1):160-5. doi: 10.1016/j.ygyno.2005.08.033. Epub 2005 Sep 29. Gynecol Oncol. 2006. PMID: 16198398 Clinical Trial.

3

Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study.

Kuo DY, Blank SV, Christos PJ, Kim M, Caputo TA, Pothuri B, Hershman D, Goldman N, Ivy PS, Runowicz CD, Muggia F, Goldberg GL, Einstein MH. Kuo DY, et al. Among authors: blank sv. Gynecol Oncol. 2010 Mar;116(3):442-6. doi: 10.1016/j.ygyno.2009.10.082. Epub 2009 Nov 20. Gynecol Oncol. 2010. PMID: 19931137 Free PMC article. Clinical Trial.

4

Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment.

Blank SV, Christos P, Curtin JP, Goldman N, Runowicz CD, Sparano JA, Liebes L, Chen HX, Muggia FM. Blank SV, et al. Gynecol Oncol. 2010 Dec;119(3):451-6. doi: 10.1016/j.ygyno.2010.08.008. Epub 2010 Sep 15. Gynecol Oncol. 2010. PMID: 20837357 Free PMC article. Clinical Trial.

5

Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?

Kwa M, Baumgartner R, Shavit L, Barash I, Michael J, Puzanov I, Kopolovic J, Rosengarten O, Blank S, Curtin JP, Gabizon A, Muggia F. Kwa M, et al. Oncologist. 2012;17(12):1534-40. doi: 10.1634/theoncologist.2011-0422. Epub 2012 May 23. Oncologist. 2012. PMID: 22622146 Free PMC article.

6

Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer.

Verschraegen CF, Czok S, Muller CY, Boyd L, Lee SJ, Rutledge T, Blank S, Pothuri B, Eberhardt S, Muggia F. Verschraegen CF, et al. Ann Oncol. 2012 Dec;23(12):3104-3110. doi: 10.1093/annonc/mds172. Epub 2012 Jul 31. Ann Oncol. 2012. PMID: 22851407 Free article. Clinical Trial.

7

A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer.

Stein SM, Tiersten A, Hochster HS, Blank SV, Pothuri B, Curtin J, Shapira I, Levinson B, Ivy P, Joseph B, Guddati AK, Muggia F. Stein SM, et al. Among authors: blank sv. Int J Gynecol Cancer. 2013 Nov;23(9):1577-82. doi: 10.1097/IGC.0b013e3182a809e0. Int J Gynecol Cancer. 2013. PMID: 24172094 Free PMC article. Clinical Trial.

8

Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer.

Aghajanian C, Goff B, Nycum LR, Wang Y, Husain A, Blank S. Aghajanian C, et al. Gynecol Oncol. 2014 Apr;133(1):105-10. doi: 10.1016/j.ygyno.2014.02.003. Epub 2014 Feb 6. Gynecol Oncol. 2014. PMID: 24508841 Clinical Trial.

9

Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.

Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, Ivanov I, Bell MC, Blank SV, DiSilvestro P, Hamilton CA, Tewari KS, Wakeley K, Kauff ND, Yamada SD, Rodriguez G, Skates SJ, Alberts DS, Walker JL, Minasian L, Lu K, Greene MH. Sherman ME, et al. Among authors: blank sv. J Clin Oncol. 2014 Oct 10;32(29):3275-83. doi: 10.1200/JCO.2013.54.1987. Epub 2014 Sep 8. J Clin Oncol. 2014. PMID: 25199754 Free PMC article. Clinical Trial.

10

Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.

Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV. Aghajanian C, et al. Among authors: blank sv. Gynecol Oncol. 2015 Oct;139(1):10-6. doi: 10.1016/j.ygyno.2015.08.004. Epub 2015 Aug 10. Gynecol Oncol. 2015. PMID: 26271155 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

128 results

Search Page